3SBio (SEHK:1530) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

1530 주식 개요

투자 지주 회사인 3SBio는 중국 본토와 해외에서 바이오 의약품을 개발, 생산, 마케팅 및 판매하는 회사입니다.

1530 기본 분석
눈송이 점수
가치 평가	5/6
미래 성장	3/6
과거 실적	2/6
재무 상태	6/6
배당금	3/6

보상

공정 가치 추정치보다 낮은 55.1% 에서 거래

수익은 매년 12.65% 증가할 것으로 예상됩니다.

동종업계 및 업계 대비 좋은 가치로 거래

위험 분석

불안정한 배당 실적

3SBio Inc. 경쟁사

Shanghai Haohai Biological Technology

SEHK:6826

HK$14.0b

Shanghai Henlius Biotech

SEHK:2696

HK$12.4b

Shandong Boan Biotechnology

SEHK:6955

HK$5.2b

Essex Bio-Technology

SEHK:1061

HK$1.4b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 3SBio
과거 주가
현재 주가	HK$6.41
52주 최고치	HK$7.69
52주 최저치	HK$4.91
베타	0.68
11개월 변경	5.78%
3개월 변경 사항	-0.47%
1년 변경 사항	-2.14%
33년 변화	-16.21%
5년 변화	-52.59%
IPO 이후 변화	-31.44%

최근 뉴스 및 업데이트

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Sep 26

Shareholders Will Probably Hold Off On Increasing 3SBio Inc.'s (HKG:1530) CEO Compensation For The Time Being

Jun 19

Recent updates

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Sep 26

Shareholders Will Probably Hold Off On Increasing 3SBio Inc.'s (HKG:1530) CEO Compensation For The Time Being

Jun 19

An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 50% Undervalued

Nov 21

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Sep 10

3SBio Inc. (HKG:1530) Shares Could Be 38% Below Their Intrinsic Value Estimate

Aug 22

3SBio Inc.'s (HKG:1530) Intrinsic Value Is Potentially 48% Above Its Share Price

May 21

Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly

Apr 16

What Kind Of Shareholders Hold The Majority In 3SBio Inc.'s (HKG:1530) Shares?

Mar 11

Is 3SBio Inc.'s (HKG:1530) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Feb 18

An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 38% Undervalued

Jan 31

A Look At 3SBio's (HKG:1530) Share Price Returns

Jan 03

Are Insiders Buying 3SBio Inc. (HKG:1530) Stock?

Dec 16

What Is The Ownership Structure Like For 3SBio Inc. (HKG:1530)?

Dec 01

주주 수익률

	1530	HK Biotechs	HK 마켓
7D	12.5%	8.5%	10.9%
1Y	-2.1%	-7.9%	13.4%

수익률 대 산업: 1530 지난 1년 동안 -19.5 %를 반환한 Hong Kong Biotechs 산업을 초과했습니다.

수익률 대 시장: 1530 지난 1년 동안 2.1 %를 반환한 Hong Kong 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is 1530's price volatile compared to industry and market?
1530 volatility
1530 Average Weekly Movement	4.9%
Biotechs Industry Average Movement	7.4%
Market Average Movement	6.8%
10% most volatile stocks in HK Market	13.7%
10% least volatile stocks in HK Market	3.5%

안정적인 주가: 1530 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: 1530 의 주간 변동성( 5% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
1993	5,607	Jing Lou	www.3sbio.com

투자 지주 회사인 3SBio는 중국 본토 및 해외에서 바이오 의약품을 개발, 생산, 마케팅 및 판매하는 회사입니다. 이 회사는 화학요법으로 인한 혈소판 감소증과 면역성 혈소판 감소증 치료를 위한 재조합 인간 혈소판 생성인자 TPIAO, HER2 양성 전이성 유방암 치료를 위한 항 HER2 단일 클론 항체 킵터빈, 사전 충전 수액 주사액인 TNF를 공급하고 있습니다. 또한 수용체 융합 종양괴사인자 억제제인 이사이푸, 탈모 치료를 위한 일반의약품인 만디미녹시딜 팅크, 에리스로포이에틴 주사제인 에피오와 세포, 저분자량 헤파린 칼슘 주사제인 스패린 등을 공급하고 있습니다.

3SBio Inc. 기본 사항 요약

3SBio 의 수익과 매출은 시가총액과 어떻게 비교하나요?
1530 기본 통계
시가총액	HK$15.10b
수익(TTM)	HK$1.84b
수익(TTM)	HK$9.33b

8.2x

P/E 비율

1.6x

P/S 비율

1530 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
1530 손익 계산서(TTM)
수익	CN¥8.42b
수익 비용	CN¥1.18b
총 이익	CN¥7.24b
기타 비용	CN¥5.58b
수익	CN¥1.66b

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	0.70
총 마진	85.94%
순이익 마진	19.69%
부채/자본 비율	24.7%

1530 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

배당금

3.9%

현재 배당 수익률

34%

지급 비율

1530 주식 개요

보상

위험 분석

3SBio Inc. 경쟁사

SEHK:6826

HK$14.0b

SEHK:2696

HK$12.4b

SEHK:6955

HK$5.2b

SEHK:1061

HK$1.4b

가격 내역 및 성능

최근 뉴스 및 업데이트

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Co-Founder recently bought HK$1.5m worth of stock

First half 2024 earnings: EPS and revenues exceed analyst expectations

3SBio Inc. to Report First Half, 2024 Results on Aug 22, 2024

Upcoming dividend of HK$0.25 per share

Shareholders Will Probably Hold Off On Increasing 3SBio Inc.'s (HKG:1530) CEO Compensation For The Time Being

Recent updates

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Co-Founder recently bought HK$1.5m worth of stock

First half 2024 earnings: EPS and revenues exceed analyst expectations

3SBio Inc. to Report First Half, 2024 Results on Aug 22, 2024

Upcoming dividend of HK$0.25 per share

Shareholders Will Probably Hold Off On Increasing 3SBio Inc.'s (HKG:1530) CEO Compensation For The Time Being

There's Reason For Concern Over 3SBio Inc.'s (HKG:1530) Price

3Sbio Inc. Announces Management Changes

Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly

New minor risk - Dividend sustainability

3SBio Inc., Annual General Meeting, Jun 25, 2024

3SBio Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024

Pinning Down 3SBio Inc.'s (HKG:1530) P/E Is Difficult Right Now

Mandi Foam of 3SBio Inc. Approves for Market Launch

These 4 Measures Indicate That 3SBio (HKG:1530) Is Using Debt Safely

Is Now The Time To Put 3SBio (HKG:1530) On Your Watchlist?

First half 2023 earnings: EPS and revenues exceed analyst expectations

Is 3SBio (HKG:1530) A Risky Investment?

First half 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.39 in 1H 2022)

3SBio Inc. to Report First Half, 2023 Results on Aug 24, 2023

Calculating The Fair Value Of 3SBio Inc. (HKG:1530)

3Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer

With EPS Growth And More, 3SBio (HKG:1530) Makes An Interesting Case

3SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market

Upcoming dividend of HK$0.10 per share at 1.3% yield

3SBio Inc., Annual General Meeting, Jun 20, 2023

3SBio (HKG:1530) Has A Pretty Healthy Balance Sheet

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Is Now The Time To Put 3SBio (HKG:1530) On Your Watchlist?

Now 22% undervalued

Is 3SBio Inc. (HKG:1530) Trading At A 23% Discount?

3SBio Inc. Announces Resignation of Tang Ke as Non-Executive Director

3Sbio Inc. Announces Executive Changes

Do 3SBio's (HKG:1530) Earnings Warrant Your Attention?

Less than half of directors are independent

Investor sentiment improved over the past week

We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

Investor sentiment improved over the past week

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

3SBio Inc. (HKG:1530) Shares Could Be 49% Below Their Intrinsic Value Estimate

First half 2022 earnings released: EPS: CN¥0.39 (vs CN¥0.35 in 1H 2021)

3SBio Inc. to Report Q2, 2022 Results on Aug 24, 2022

3SBio Inc. Approves Final Dividend for the Year Ended 31 December 2021

Upcoming dividend of HK$0.20 per share

3Sbio Inc. Announces Phase III Clinical Study of It's Recombinant Human Thrombopoietin (Rhtpo) Injection (Tpiao )

Full year 2021 earnings: EPS exceeds analyst expectations

Less than half of directors are independent

Is 3SBio Inc. (HKG:1530) Trading At A 45% Discount?

3SBio Inc., Annual General Meeting, Jun 22, 2022

We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

Full year 2021 earnings: EPS exceeds analyst expectations

3Sbio Inc. Proposes Final Cash Dividend for the Year Ended 31 December 2021, Payable on or around 11 July 2022

Investor sentiment improved over the past week

3SBio Inc. Provides Earnings Guidance for the Year Ended 31 December 2021

We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 50% Undervalued

First half 2021 earnings released: EPS CN¥0.35 (vs CN¥0.28 in 1H 2020)

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Investor sentiment improved over the past week